Regencell Bioscience Holdings Limited's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Regencell Bioscience Holdings Limited (RGC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Regencell Bioscience Holdings Limited vs Its Competitors
- TTM: Trailing 12-month revenue of 3,068M vs 258,775M combined for tracked competitors (1.2% combined share).
- Scale: Regencell Bioscience Holdings Limited ranks #2 of 37 companies by market capitalization in the Legal Cannabis industry, holding 28.0% of industry market cap.
- Peer differentiation: Revenue per employee of $15.34M compares with $0.91M for the peer group (16.8x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Regencell Bioscience Holdings Limited vs. its Competitors, Q4 2025
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Regencell Bioscience Holdings Limited and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Regencell Bioscience Holdings Limited | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Regencell Bioscience Holdings Limited's competitor groups requires a Commercial License.
Regencell Bioscience Holdings Limited's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Regencell Bioscience Holdings Limited | - | - | - | - |
| Competitors combined (4) | ||||
| High-Confidence Competitors (3) | ||||
| Similar-Size Competitors (6) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
RGC Stock Performance relative to its Competitors
RGC Stock Performance relative to High-Confidence Competitors
RGC Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Eli Lilly And Company | 282.9% | Outperformed |
| 2 | Pfizer Inc | 282.9% | Outperformed |
| 3 | Novartis Ag | 282.9% | Outperformed |
| 4 | Astrazeneca Plc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Regencell Bioscience Holdings Limited's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Regencell Bioscience Holdings Limited's Comment on Competition and Industry Peers
Publicly Traded Peers of Regencell Bioscience Holdings Limited
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Regencell Bioscience Holdings Limited | 3,065.83 | 3,068.30 |
| Eli Lilly And Company | 1,058,837.89 | 79,665.80 |
| Novartis Ag | 287,150.40 | 56,674.00 |
| Astrazeneca Plc | 259,526.30 | 58,739.00 |
| Pfizer Inc | 163,675.28 | 63,696.00 |
| SUBTOTAL | 1,772,255.70 | 261,843.10 |
Sources: Regencell Bioscience Holdings Limited's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Regencell Bioscience Holdings Limited versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Regencell Bioscience Holdings Limited's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Pfizer Inc. | Named by the company | 85% |
| AstraZeneca | Named by the company | 85% |
| Eli Lilly and Company | Named by the company | 85% |
| Fusion Autism Center | Named by the company | 85% |
| Otsuka Holdings Co. Limited | Named by the company | 85% |
| Novartis Ag | Named by the company | 85% |
| Shire Plc | Named by the company | 85% |
| Neos Therapeutics Inc | Named by the company | 85% |
| Medicines Co | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Regencell Bioscience Holdings Limited's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Regencell Bioscience Holdings Limited's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Regencell Bioscience Holdings Limited's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Regencell Bioscience Holdings Limited | 3,066 | 15,341,500 | -17,921 |
| Eli Lilly And Company | 1,058,838 | 1,593,316 | 534,224 |
| Novartis Ag | 287,150 | 752,973 | 185,566 |
| Astrazeneca Plc | 259,526 | 706,847 | 123,141 |
| Pfizer Inc | 163,675 | 849,280 | 58,267 |
| PEERS TOTAL | 1,769,190 | 913,214 | 195,087 |
Regencell Bioscience Holdings Limited's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Pfizer Inc | United States 58.91 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Regencell Bioscience Holdings Limited's Position in Industry Market Structure
Market-capitalization share and concentration across all 24 companies in Regencell Bioscience Holdings Limited's industry classification, broader than the peer set above. Market cap in millions of $.Regencell Bioscience Holdings Limited ranks #2 of 24 companies by market capitalization in its industry, holding 27.97 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 2,480, indicating a moderately concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Definium Therapeutics Inc | 4,251 | 38.78 % |
| 2 | Regencell Bioscience Holdings Limited | 3,066 | 27.97 % |
| 3 | Cronos Group Inc | 1,279 | 11.67 % |
| 4 | Tilray Brands Inc | 450 | 4.10 % |
| 5 | Canopy Growth Corporation | 1,234 | 5.2% |
| 6 | Sndl Inc | 1,234 | 5.2% |
| 7 | Usana Health Sciences Inc | 1,234 | 5.2% |
| 8 | Niagen Bioscience Inc | 1,234 | 5.2% |
| 9 | Aurora Cannabis Inc | 1,234 | 5.2% |
| 10 | Mediwound Ltd | 1,234 | 5.2% |
Market cap and industry share for the rest of Regencell Bioscience Holdings Limited's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Regencell Bioscience Holdings Limited's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Definium Therapeutics Inc | 4,251 | 266.79 % |
| 2 | Regencell Bioscience Holdings Limited | 3,066 | -58.92 % |
| 3 | Cronos Group Inc | 1,279 | 27.46 % |
| 4 | Tilray Brands Inc | 1,234 | 12.3% |
| 5 | Canopy Growth Corporation | 1,234 | 12.3% |
| 6 | Sndl Inc | 1,234 | 12.3% |
| 7 | Usana Health Sciences Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Regencell Bioscience Holdings Limited's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Regencell Bioscience Holdings Limited's BCG Growth-Share Matrix
Relative market share (vs Regencell Bioscience Holdings Limited's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Regencell Bioscience Holdings Limited falls in the Dog quadrant: relative market share of 0.72x vs its largest competitor, in an industry growing revenue 2.8% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution. A caveat worth reading alongside this chart: Definium Therapeutics Inc alone holds 39% of this industry's market cap. In an industry this dominated by one leader, the framework will place nearly every OTHER company in "Dog" or "Question Mark" purely because relative share is measured against that leader, regardless of how strong those other companies actually are on their own fundamentals. Check the Profitability, Valuation and Financial Strength sections above before treating this quadrant label as a verdict.
Regencell Bioscience Holdings Limited's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 2,480 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Regencell Bioscience Holdings Limited's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Regencell Bioscience Holdings Limited's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Regencell Bioscience Holdings Limited's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Regencell Bioscience Holdings Limited falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Regencell Bioscience Holdings Limited's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
No rule matched.
Threats
- Industry dominated by Definium Therapeutics Inc , holding 38.78 % of industry market cap.
- Tracked peer group's revenue run-rate is broadly decelerating (-9.2% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Regencell Bioscience Holdings Limited's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Regencell Bioscience Holdings Limited | 3.65 | 7.39 | 0.00 |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Regencell Bioscience Holdings Limited's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Regencell Bioscience Holdings Limited | Q2 2025 | - | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| PEERS TOTAL | +12.8 % | +12.7 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Regencell Bioscience Holdings Limited's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Regencell Bioscience Holdings Limited | Q2 2025 | - | +2,740.2 % |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
Regencell Bioscience Holdings Limited's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Regencell Bioscience Holdings Limited | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Regencell Bioscience Holdings Limited's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Regencell Bioscience Holdings Limited | - | 1.00 |
| Eli Lilly And Company | 39.77 | 13.29 |
| Novartis Ag | 20.53 | 5.07 |
| Astrazeneca Plc | 25.38 | 4.42 |
| Pfizer Inc | 37.66 | 2.57 |
| PEERS AVERAGE | 32.06 | 6.77 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.